GRAPPA Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Philip Mease MD.
-
Upload
lenard-sherman -
Category
Documents
-
view
217 -
download
2
Transcript of GRAPPA Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Philip Mease MD.
![Page 1: GRAPPA Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Philip Mease MD.](https://reader035.fdocuments.in/reader035/viewer/2022062716/56649dbb5503460f94aac9c0/html5/thumbnails/1.jpg)
GRAPPAGroup for Research and
Assessment of Psoriasis and Psoriatic Arthritis
Philip Mease MD
![Page 2: GRAPPA Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Philip Mease MD.](https://reader035.fdocuments.in/reader035/viewer/2022062716/56649dbb5503460f94aac9c0/html5/thumbnails/2.jpg)
Agenda
• GRAPPA: History, objectives, projects – Mease
• PsA domains of inquiry and instruments of assessment. OMERACT – Gladman
• Skin assessments – Krueger
• Can GRAPPA be of use to dermatologists? Where do we go from here?
![Page 3: GRAPPA Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Philip Mease MD.](https://reader035.fdocuments.in/reader035/viewer/2022062716/56649dbb5503460f94aac9c0/html5/thumbnails/3.jpg)
Acknowledgements• Major Sponsors
– Abbott – Amgen– Biogen– Centocor– Genentech– Novartis – Schering-Plough – Serono – Wyeth
• Minor Sponsors – Aventis
![Page 4: GRAPPA Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Philip Mease MD.](https://reader035.fdocuments.in/reader035/viewer/2022062716/56649dbb5503460f94aac9c0/html5/thumbnails/4.jpg)
Needs• Background of burgeoning interest in psoriasis and PsA treatment with
advent of biologics• Improve awareness of and communication between experts in PsA and
PSO, especially between rheumatologists and dermatologists• Identify and study key domains of inquiry in PsA and PSO• Develop updated classification criteria of PsA (CASPAR)• Validate and standardize outcome assessment tools in PsA and PSO, both
for basic clinical and therapeutic studies• Improve awareness of and communication between PsA/PSO experts and
other interested entities, including patient leagues, regulatory agencies industry, other physicians, and the public
• Improve educational efforts about PsA and PSO• Improve conduct and standardization of clinical registries• Development of treatment guidelines
![Page 5: GRAPPA Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Philip Mease MD.](https://reader035.fdocuments.in/reader035/viewer/2022062716/56649dbb5503460f94aac9c0/html5/thumbnails/5.jpg)
History
• Model: ASAS (Assessments in Ankylosing Spondylitis) working group est. 1995
• Core rheumatology group: CASPAR est. 2000• Idea conception: NY AS meeting 8/02• Idea discussion: Gent SpA meeting 10/02• PsA working group authorized: CASPAR meeting, ACR
10/02• Initial rheumatology group meetings: EULAR, Lisbon
6/03, ACR Orlando 2003• Inaugural combined rheum-derm meeting planning: 8/03
NYC
![Page 6: GRAPPA Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Philip Mease MD.](https://reader035.fdocuments.in/reader035/viewer/2022062716/56649dbb5503460f94aac9c0/html5/thumbnails/6.jpg)
GRAPPA Steering Committee
• Steering Committee– Christian Antoni– Dafna Gladman– Desiree van der Heijde– Philip Helliwell– Joachim (Jochen) Kalden– Artie Kavanaugh– Gerald (Jerry) Krueger– Philip Mease– Alan Menter– Peter Nash– Christopher (Chris) Ritchlin– Josef Smolen– William (Will) Taylor
![Page 7: GRAPPA Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Philip Mease MD.](https://reader035.fdocuments.in/reader035/viewer/2022062716/56649dbb5503460f94aac9c0/html5/thumbnails/7.jpg)
GRAPPA Membership
• ~ 100 members from US, Canada, Europe and Australia/New Zealand
• ~ 50% rheums
• ~ 10% derms
• ~ 40% industry, regulatory, patient service league representatives
![Page 8: GRAPPA Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Philip Mease MD.](https://reader035.fdocuments.in/reader035/viewer/2022062716/56649dbb5503460f94aac9c0/html5/thumbnails/8.jpg)
Personnel
• Project Manager– Robin Shapiro (Health Advocacy Strategies)
![Page 9: GRAPPA Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Philip Mease MD.](https://reader035.fdocuments.in/reader035/viewer/2022062716/56649dbb5503460f94aac9c0/html5/thumbnails/9.jpg)
GRAPPA Projects
• Meetings: Specialty specific meetings adjacent to ACR, EULAR, ?AAD, ?EADV
• Publications: Supplement to Annals of Rheumatic Disease. ? GRAPPA journal
• Classification criteria: CASPAR• Prioritization of domains of inquiry: Delphi
exercise• Outcome measures: Standardization and
validation; OMERACT
![Page 10: GRAPPA Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Philip Mease MD.](https://reader035.fdocuments.in/reader035/viewer/2022062716/56649dbb5503460f94aac9c0/html5/thumbnails/10.jpg)
ARD Journal Supplement Table of Contents
• GRAPPA - Introduction
• ASAS Working Group as a Model for GRAPPA
• PsA and PsO: Clinical Features, Pathophysiology, Immunology
• PsA Clinical Features I: History of Identification, Criteria Efforts
• PsA Clinical Features II: Epidemiology, Clinical Features, QOL
• PsA Clinical Features III: Update on Clinical Picture through Trial Cohorts
• Psoriasis Epidemiology, Clinical Features and QOL
• DISCUSSION: Clinical Features, Epidemiology, Classification Criteria
• PsA Immunology and Synovial and Extra-articular Histopathology
• PsA Genetics and Genetic Epidemiology
• Psoriasis Genetics
• Psoriasis Pathophysiology
• DISCUSSION: Immunology, Cellular Pathology, Genetics, Etc.
![Page 11: GRAPPA Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Philip Mease MD.](https://reader035.fdocuments.in/reader035/viewer/2022062716/56649dbb5503460f94aac9c0/html5/thumbnails/11.jpg)
Supplement Table of Contents
• PsA and Pso: Treatment• PsA Treatment: NSAIDs and DMARDs• PsA Treatment: Anti-TNF Medications• PsA Treatment: Emerging Biologics• PsO Treatment: Traditional Therapies• PsO Treatment: Current and Emerging Directed
Therapies• DISCUSSION: treatment of PsA and Pso
![Page 12: GRAPPA Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Philip Mease MD.](https://reader035.fdocuments.in/reader035/viewer/2022062716/56649dbb5503460f94aac9c0/html5/thumbnails/12.jpg)
Supplement Table of Contents
• Lessons from Clinical Trials, Clinical Practice• Pros/Cons of lumping spondylarthropathies together
• Role of Patients, Patient Service Organizations• Assessment: Domains and Instruments
– Science of Assessments
– PsA Assessment Tools in Clinical Trials
– PsA Assessment Instruments: Imaging
– PsO Assessment Tools in Clinical Trials
– Ethics, Practical Issues in Conducting Clinical Trials
– DISCUSSION:Assessment
![Page 13: GRAPPA Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Philip Mease MD.](https://reader035.fdocuments.in/reader035/viewer/2022062716/56649dbb5503460f94aac9c0/html5/thumbnails/13.jpg)
Supplement Table of Contents
• PsA Clinical Registries and Genomics– Introduction/Overview on Clinical Registries– PsA Clinical Registries and Genomics– PsO Clinical Registries and Genomics
• Developing Assessment Methodology in PsA– ASAS Working Group Process– OMERACT Process– Delphi Exercise on Domains in PsA– Consensus Exercise on Domains in PsA
• OMERACT• EPILOGUE
![Page 14: GRAPPA Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Philip Mease MD.](https://reader035.fdocuments.in/reader035/viewer/2022062716/56649dbb5503460f94aac9c0/html5/thumbnails/14.jpg)
Group median scores for DCART
0
2
4
6
8
10
12
14
Active
JC
Xray d
amag
e
Patient
globa
lPain
Physic
al func
tion
Acute
pha
seQOL
Dactyliti
s
Enthe
sitis
Damaged
JCSkin
Physic
ian g
lobal
Mor
ning st
iffnes
s
Spinal
mob
ility
- lumbar
Utility
inde
xSlee
p
Extra-
skele
tal
Fatigu
e
Sacro
iliac t
ests
Xray j
oint infla
mmatio
n
Spinal
mob
ility
- tho
racic
Spinal
mob
ility
- cer
vical
Tendini
tis
Obser
ved
phys
ical
Work
limita
tions
Work
incap
acity
Round1 Median Round2 Median Round3 Median
DCART – results #1
![Page 15: GRAPPA Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Philip Mease MD.](https://reader035.fdocuments.in/reader035/viewer/2022062716/56649dbb5503460f94aac9c0/html5/thumbnails/15.jpg)
Core Sets in PsA• Domain– Joint assessment– Axial assessment*– Skin assessment– Pain– Patient global– Physician global– Function*– Fatigue*– Enthesial assessment*– Dactylitis assessment*– Stiffness– Acute phase reactants– Xray*– MRI*– Ultrasound*– Clinical subset response*
*Needs development/validation
• Instrument– T/S joint count– ?– PASI, Target lesion, Global– VAS– VAS– VAS– HAQ, SF-36, DLQI– Krupp, MFI, FACIT, one question– Mander, MASES, San Francisco– 0-4 scale– Duration minutes– ESR, CRP– MSharp, Larsen, Steinbrocker– ?– ?– Need clear guidelines to define clinical subsets in
order to assess subset response
![Page 16: GRAPPA Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Philip Mease MD.](https://reader035.fdocuments.in/reader035/viewer/2022062716/56649dbb5503460f94aac9c0/html5/thumbnails/16.jpg)
OMERACT
• International organization of rheumatologists, industry and regulatory representatives
• Development of standardized and validated outcome measures in all fields of rheumatology, developed in an evidence-based and consensual fashion
• Meets every two years; next is OMERACT VII in US (CA), May 12-16
![Page 17: GRAPPA Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Philip Mease MD.](https://reader035.fdocuments.in/reader035/viewer/2022062716/56649dbb5503460f94aac9c0/html5/thumbnails/17.jpg)
OMERACT FILTER
• Truth (validity)
• Discrimination (reproducibility and responsiveness)
• Feasibility
![Page 18: GRAPPA Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Philip Mease MD.](https://reader035.fdocuments.in/reader035/viewer/2022062716/56649dbb5503460f94aac9c0/html5/thumbnails/18.jpg)
GRAPPA Projects (cont.)
• Treatment guidelines• Support of patient service leagues in
education process• Support, standardization of clinical
registries• Intranet web site for online work and
communication: Big Mind Catalyst• Joint rheum-derm meetings
![Page 19: GRAPPA Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Philip Mease MD.](https://reader035.fdocuments.in/reader035/viewer/2022062716/56649dbb5503460f94aac9c0/html5/thumbnails/19.jpg)
Center Page
This is the initial page you access after logging in, which
lists all of the conferences that are available to you.
![Page 20: GRAPPA Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Philip Mease MD.](https://reader035.fdocuments.in/reader035/viewer/2022062716/56649dbb5503460f94aac9c0/html5/thumbnails/20.jpg)
Topic Page:
This is the heart of the Catalyst workspace where all of the content is posted.
Each topic is a single conversation on a
particular topic and is displayed linearly.
![Page 21: GRAPPA Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Philip Mease MD.](https://reader035.fdocuments.in/reader035/viewer/2022062716/56649dbb5503460f94aac9c0/html5/thumbnails/21.jpg)
How GRAPPA Can use BigMind Catalyst
• Create, edit and distribute documents• Asynchronous discussion within a subcommittee• Create and distribute agendas and minutes• Library of documents, including links to websites and webcasts• Shared calendar of events• Work through issues with international membership present in the
conversation• Create “group memory”over time… helping to develop and
standardize language and procedures• Search conversation history• Web site for public access• Links to OMERACT, patient service leagues
![Page 22: GRAPPA Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Philip Mease MD.](https://reader035.fdocuments.in/reader035/viewer/2022062716/56649dbb5503460f94aac9c0/html5/thumbnails/22.jpg)
Do Psoriasis Thought Leaders Have Any Use for GRAPPA?
• Forum and methodological support for evolution of skin, QOL and other derm measures
• Forum for communication with rheums• Fostering joint research projects• Collaboration re. clinical registries, genetics
investigations• Derm-rheum collaboration with patient service
leagues• Publications• Joint derm-rheum meetings